Sun Pharma.Inds.

Part of MojoOne Strategy

Market Cap: Large Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE044A01036
NSEID: SUNPHARMA
BSEID: 524715

INR

1,802.60

-16 (-0.88%)

BSENSE

Dec 05

BSE+NSE Vol: 13.46 lacs

Click here to access the older version

{
  "main_header": {
    "sid": 948699,
    "name": "Sun Pharma.Inds.",
    "stock_name": "Sun Pharma.Inds.",
    "full_name": "Sun Pharmaceutical Industries Ltd",
    "name_url": "stocks-analysis/sun-pharmainds",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,802.60",
    "chg": -16,
    "chgp": "-0.88%",
    "dir": -1,
    "prev_price": "1,818.60",
    "mcapval": "432,504.12 Cr",
    "mcap": "Large Cap",
    "scripcode": 524715,
    "symbol": "SUNPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE044A01036",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "13.46 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MS",
      "url": "https://www.marketsmojo.com/mojostocks#!#top10",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Sun Pharmaceutical Industries: Navigating Market Dynamics as a Nifty 50 Constituent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-navigating-nifty-50-membership-and-institutional-dynamics-3748004",
        "imagepath": "",
        "date": "2025-12-05 09:21:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries among the elite group of companies that represent the Indian equity market’s large-cap segment. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the stock benefits from steady institutional interest and liquidity, factors that are crucial for price discovery and market stability.</p>\n                <p>Sun Pharma’s market capitalisation stands at approximately ₹4,36,343 crore, categorising it firmly as a large-cap entity. This scale supports its benchmark status and influe..."
      },
      {
        "title": "Sun Pharmaceutical Industries: Navigating Nifty 50 Membership and Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-navigating-nifty-50-membership-amid-mixed-market-signals-3745802",
        "imagepath": "",
        "date": "2025-12-04 09:21:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Sun Pharmaceutical Industries represents one of the largest and most liquid stocks on the National Stock Exchange of India. This membership not only highlights the company’s market capitalisation but also ensures its inclusion in numerous index-tracking funds and institutional portfolios. The stock’s market cap stands at ₹4,32,420.14 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.</p>\n                <p>Being part of the benchmark index means that Sun Pharma’s price movements have a direct bearing on the overall index performance. This relationship is particularly relevant for portfolio managers and passive investors who ..."
      },
      {
        "title": "Sun Pharmaceutical Industries: Analytical Perspective Shift Reflects Market and Financial Dynamics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-downgraded-to-buy-amid-technical-softening-and-valuation-concerns-3743156",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SunPharmaceutic_mojoScore_3743156.png",
        "date": "2025-12-03 08:25:59",
        "description": "Sun Pharmaceutical Industries has experienced a revision in its market assessment, reflecting nuanced changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This article explores the factors influencing the recent shift in analytical perspective for this leading player in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Sun Pharma.Inds.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sun-pharmainds-3742273",
        "imagepath": "",
        "date": "2025-12-02 23:05:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Sun Pharma.Inds. has seen its net sales rise significantly from ₹29,065.91 crores in March 2019 to ₹52,578.44 crores in March 2025, reflecting a robust compound growth over the six-year period. This growth underscores the company’s expanding market presence and product portfolio. Operating profit before depreciation and interest (PBDIT) excluding other income also increased from ₹6,307.59 crores in 2019 to ₹15,271.69 crores in 2025, indicating improved operational efficiency and cost management.</p>\n<p>Including other income, operating profit rose to ₹17,236.73 crores in 2025 from ₹7,333.08 crores in 2019, more than doubling in six years. Profit before tax surged from ₹3,810.20 crores in 2019 to ₹13,752.13 crores in 2025, while profit after tax follo..."
      },
      {
        "title": "Is Sun Pharma.Inds. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sun-pharmainds-technically-bullish-or-bearish-3740529",
        "imagepath": "",
        "date": "2025-12-02 09:11:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Recent Price Movements and Trend Shifts</strong></p>\n<p>As of 1 December 2025, Sun Pharma.Inds. has seen its technical trend adjust from bullish to mildly bullish. The stock closed at ₹1,807.85, slightly down from the previous close of ₹1,831.25, with intraday fluctuations ranging between ₹1,801.00 and ₹1,843.95. The 52-week price range remains broad, with a high of ₹1,910.00 and a low of ₹1,547.25, indicating a significant volatility band over the past year.</p>\n<p>This mild tempering of the bullish trend suggests that while the stock retains upward momentum, the pace of gains may be moderating. Investors should note that the current price is still comfortably above the yearly low, signalling resilience despite recent market pressures.</p>\n<p><strong>Technical Indicators: A Mixe..."
      },
      {
        "title": "Sun Pharmaceutical Industries: Technical Momentum and Market Assessment Update",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-technical-momentum-shifts-amid-mixed-market-signals-3740269",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SunPharmaceutic_technicaldot_3740269.png",
        "date": "2025-12-02 08:09:57",
        "description": "Sun Pharmaceutical Industries has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and mildly bearish signals across multiple timeframes. This update examines the recent changes in key technical indicators and price movements, providing a comprehensive view of the stock’s current market stance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sun Pharmaceutical Industries: Navigating Nifty 50 Membership and Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-strengthens-position-amid-nifty-50-benchmark-dynamics-3737638",
        "imagepath": "",
        "date": "2025-12-01 09:21:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries among the most influential and widely tracked companies on the National Stock Exchange of India. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-linked investment products such as exchange-traded funds (ETFs) and mutual funds. Consequently, the stock experiences consistent institutional participation, which can influence liquidity and price stability.</p>\n                <p>Sun Pharma’s market capitalisation stands at approximately ₹4,40,110.01 crore, categorising it firmly as a large-cap stock. This sizeable market cap supports its ..."
      },
      {
        "title": "Sun Pharmaceutical Industries: Analytical Perspective Shift Reflects Market and Financial Dynamics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-upgraded-to-strong-buy-on-robust-fundamentals-and-technicals-3734780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SunPharmaceutic_mojoScore_3734780.png",
        "date": "2025-11-28 08:13:33",
        "description": "Sun Pharmaceutical Industries has experienced a notable shift in market assessment, reflecting evolving technical indicators and financial fundamentals. This revision in the company's evaluation highlights key developments across quality, valuation, financial trends, and technical outlook, providing investors with a comprehensive understanding of its current positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sun Pharmaceutical Industries Shows Shift in Price Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-technical-momentum-shifts-to-bullish-amid-strong-buy-upgrade-3734707",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SunPharmaceutic_technicaldot_3734707.png",
        "date": "2025-11-28 08:06:38",
        "description": "Sun Pharmaceutical Industries has exhibited a notable shift in its price momentum, reflecting a complex interplay of technical indicators across multiple timeframes. Recent assessment changes highlight a transition from a mildly bullish to a bullish technical trend, underscoring evolving market dynamics within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 897,
    "sid": "948699",
    "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699"
  },
  "announcements": [
    {
      "caption": "Intimation Under Regulation 30 - Approval Of Proposal For Greenfield Project",
      "datetime": "02-Dec-2025",
      "details": "Intimation under Regulation 30 - Approval of proposal for Greenfield Project",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Dec-2025",
      "details": "Sun Pharma introduces Ilumya in India for the treatment of moderate-to-severe Plaque Psoriasis.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "26-Nov-2025",
      "details": "Press Release",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>550%</strong> dividend, ex-date: 07 Jul 25",
          "dt": "2025-07-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10",
          "dt": "2010-11-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13",
          "dt": "2013-07-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sun Pharmaceutical Industries: Navigating Market Dynamics as a Nifty 50 Constituent

2025-12-05 09:21:04

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries among the elite group of companies that represent the Indian equity market’s large-cap segment. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the stock benefits from steady institutional interest and liquidity, factors that are crucial for price discovery and market stability.

Sun Pharma’s market capitalisation stands at approximately ₹4,36,343 crore, categorising it firmly as a large-cap entity. This scale supports its benchmark status and influe...

Sun Pharmaceutical Industries: Navigating Nifty 50 Membership and Market Dynamics

2025-12-04 09:21:13

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Sun Pharmaceutical Industries represents one of the largest and most liquid stocks on the National Stock Exchange of India. This membership not only highlights the company’s market capitalisation but also ensures its inclusion in numerous index-tracking funds and institutional portfolios. The stock’s market cap stands at ₹4,32,420.14 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.

Being part of the benchmark index means that Sun Pharma’s price movements have a direct bearing on the overall index performance. This relationship is particularly relevant for portfolio managers and passive investors who ...

Sun Pharmaceutical Industries: Analytical Perspective Shift Reflects Market and Financial Dynamics

2025-12-03 08:25:59

Sun Pharmaceutical Industries has experienced a revision in its market assessment, reflecting nuanced changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This article explores the factors influencing the recent shift in analytical perspective for this leading player in the Pharmaceuticals & Biotechnology sector.

How has been the historical performance of Sun Pharma.Inds.?

2025-12-02 23:05:09

Revenue and Profit Growth

Sun Pharma.Inds. has seen its net sales rise significantly from ₹29,065.91 crores in March 2019 to ₹52,578.44 crores in March 2025, reflecting a robust compound growth over the six-year period. This growth underscores the company’s expanding market presence and product portfolio. Operating profit before depreciation and interest (PBDIT) excluding other income also increased from ₹6,307.59 crores in 2019 to ₹15,271.69 crores in 2025, indicating improved operational efficiency and cost management.

Including other income, operating profit rose to ₹17,236.73 crores in 2025 from ₹7,333.08 crores in 2019, more than doubling in six years. Profit before tax surged from ₹3,810.20 crores in 2019 to ₹13,752.13 crores in 2025, while profit after tax follo...

Is Sun Pharma.Inds. technically bullish or bearish?

2025-12-02 09:11:49

Overview of Recent Price Movements and Trend Shifts

As of 1 December 2025, Sun Pharma.Inds. has seen its technical trend adjust from bullish to mildly bullish. The stock closed at ₹1,807.85, slightly down from the previous close of ₹1,831.25, with intraday fluctuations ranging between ₹1,801.00 and ₹1,843.95. The 52-week price range remains broad, with a high of ₹1,910.00 and a low of ₹1,547.25, indicating a significant volatility band over the past year.

This mild tempering of the bullish trend suggests that while the stock retains upward momentum, the pace of gains may be moderating. Investors should note that the current price is still comfortably above the yearly low, signalling resilience despite recent market pressures.

Technical Indicators: A Mixe...

Read More

Sun Pharmaceutical Industries: Technical Momentum and Market Assessment Update
2025-12-02 08:09:57
Sun Pharmaceutical Industries has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and mildly bearish signals across multiple timeframes. This update examines the recent changes in key technical indicators and price movements, providing a comprehensive view of the stock’s current market stance within the Pharmaceuticals & Biotechnology sector.
Read More

Sun Pharmaceutical Industries: Navigating Nifty 50 Membership and Market Dynamics
2025-12-01 09:21:25

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries among the most influential and widely tracked companies on the National Stock Exchange of India. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-linked investment products such as exchange-traded funds (ETFs) and mutual funds. Consequently, the stock experiences consistent institutional participation, which can influence liquidity and price stability.

Sun Pharma’s market capitalisation stands at approximately ₹4,40,110.01 crore, categorising it firmly as a large-cap stock. This sizeable market cap supports its ...
Read More
Sun Pharmaceutical Industries: Analytical Perspective Shift Reflects Market and Financial Dynamics
2025-11-28 08:13:33
Sun Pharmaceutical Industries has experienced a notable shift in market assessment, reflecting evolving technical indicators and financial fundamentals. This revision in the company's evaluation highlights key developments across quality, valuation, financial trends, and technical outlook, providing investors with a comprehensive understanding of its current positioning within the Pharmaceuticals & Biotechnology sector.
Read More
Sun Pharmaceutical Industries Shows Shift in Price Momentum Amid Mixed Technical Signals
2025-11-28 08:06:38
Sun Pharmaceutical Industries has exhibited a notable shift in its price momentum, reflecting a complex interplay of technical indicators across multiple timeframes. Recent assessment changes highlight a transition from a mildly bullish to a bullish technical trend, underscoring evolving market dynamics within the Pharmaceuticals & Biotechnology sector.
Read More
View All News